By David Brick, Senior Director, Data Science, IDBS
Growing support for personalized medicines, managing external manufacturing, and supply chain disruptions are increasing costs, complexity, and risks for the pharmaceutical and biotech (“BioPharmaceutical”) industry. Despite the integral value of CDMOs to drug innovation and production, ensuring data integrity across multiple organizations remains a significant issue that requires a solution.
A holistic approach to data management may be the only way for BioPharma companies to gain control at every step of the product lifecycle and build the foundation for lasting competitiveness. The cornerstone of this foundation is a cloud-based digital transformation creates an end-to-end, contextualized view of the whole product and patient lifecycle.